Compare UTHR & CHKP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTHR | CHKP |
|---|---|---|
| Founded | 1996 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5B | 19.4B |
| IPO Year | 1999 | 1996 |
| Metric | UTHR | CHKP |
|---|---|---|
| Price | $485.36 | $180.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 19 |
| Target Price | ★ $498.83 | $229.11 |
| AVG Volume (30 Days) | 343.7K | ★ 1.3M |
| Earning Date | 02-25-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.08 | ★ 24.68 |
| EPS | ★ 26.38 | 9.12 |
| Revenue | ★ $3,128,400,000.00 | $2,684,200,000.00 |
| Revenue This Year | $13.57 | $8.42 |
| Revenue Next Year | $5.72 | $6.11 |
| P/E Ratio | ★ $18.16 | $19.32 |
| Revenue Growth | ★ 13.50 | 6.31 |
| 52 Week Low | $266.98 | $170.49 |
| 52 Week High | $519.99 | $234.36 |
| Indicator | UTHR | CHKP |
|---|---|---|
| Relative Strength Index (RSI) | 54.06 | 42.97 |
| Support Level | $462.02 | $170.49 |
| Resistance Level | $487.50 | $180.00 |
| Average True Range (ATR) | 9.08 | 4.88 |
| MACD | 1.70 | -0.27 |
| Stochastic Oscillator | 88.42 | 44.25 |
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Check Point Software Technologies is a pure-play cybersecurity vendor. The company offers solutions for network, endpoint, cloud, and mobile security in addition to security management. Check Point, a software specialist, sells to enterprises, businesses, and consumers. Around 50% of revenue is generated in Europe, the Middle East, and Africa, 40% from the Americas, and 10% from the Asia-Pacific region. The firm, based in Tel Aviv, Israel, was founded in 1993 and has about 5,000 employees.